Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume

Pharming Group (NASDAQ:PHAR) saw unusually-strong trading volume on Friday . Approximately 4,528 shares were traded during trading, an increase of 72% from the previous session’s volume of 2,625 shares.The stock last traded at $9.35 and had previously closed at $9.33.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research note on Thursday, March 14th.

Pharming Group Price Performance

The company has a 50 day simple moving average of $11.05 and a 200 day simple moving average of $11.51. The company has a market capitalization of $627.48 million, a price-to-earnings ratio of -68.67 and a beta of 0.16. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.62.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, March 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.08). The business had revenue of $81.20 million for the quarter, compared to analyst estimates of $71.83 million. Pharming Group had a negative return on equity of 4.53% and a negative net margin of 4.13%. As a group, research analysts predict that Pharming Group will post -0.02 EPS for the current year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. Silverberg Bernstein Capital Management LLC acquired a new stake in Pharming Group (NASDAQ:PHAR) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 17,710 shares of the company’s stock, valued at approximately $202,000. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks.